Generic Name and Formulations:
Hepatitis A inactivated 720 ELISA Units (EL.U.), hepatitis B surface antigen (recombinant) 20mcg; per mL; susp for IM inj; aluminum adsorbed; contains trace amounts of thimerosal, formalin, neomycin, yeast protein.
Indications for TWINRIX:
Hepatitis A and hepatitis B immunization.
≥18yrs: 1 inj IM in deltoid area at 0-, 1-, and 6 months. Alternate 4-dose schedule: 1 inj IM in deltoid area at 0-, 7-, and 21 to 30-days followed by booster dose at month 12.
<18yrs: not recommended.
May defer in acute febrile illness or active infection. Bleeding disorders. Thrombocytopenia. Immunodeficiency: may get suboptimal response. Have epinephrine (1:1000) inj available. If given with immune globulin, use separate syringe and different site. Pregnancy (Cat.C). Nursing mothers.
Immunosuppressives may reduce efficacy.
Inj site reactions, headache, fatigue, GI upset, fever.
Register pregnant patients exposed to Twinrix by calling (888) 452-9622. Report adverse events to VAERS by calling (800) 822-7967.
Single-dose vials—1, 10; Single-dose prefilled syringes—5
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies